All > Osteopenia > Congestive Heart Failure

Ertugliflozin 5 mg for Type 2 Diabetes

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Type 2 Diabetes+1 MoreErtugliflozin 5 mg - Drug
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial will see if a SGLTi2 inhibitor alters cardiac metabolism in people with HFpEF and DM2 compared to placebo.

Eligible Conditions
  • Type 2 Diabetes
  • Diastolic Heart Failure

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Similar Trials

1
Ustekinumab
1
Tofacitinib 5 mg
1
Tofacitinib 10 mg

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 12 weeks

12 weeks
Left ventricular mass index (gm/m2), as measured by cardiac MRI
Peak VO2, ml/kg/min, as measured by metabolic gas exchange
Serum ketone bodies (betahydroxybutyrate)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

2
Ustekinumab
2
Tofacitinib 5 mg
2
Tofacitinib 10 mg

Side Effects for

Ertugliflozin 15 mg
10%Upper respiratory tract infection
10%Back pain
9%Hypoglycaemia
8%Urinary tract infection
7%Weight decreased
5%Arthralgia
5%Influenza
5%Headache
4%Cough
4%Viral upper respiratory tract infection
1%Peripheral ischaemia
This histogram enumerates side effects from a completed 2017 Phase 3 trial (NCT02033889) in the Ertugliflozin 15 mg ARM group. Side effects include: Upper respiratory tract infection with 10%, Back pain with 10%, Hypoglycaemia with 9%, Urinary tract infection with 8%, Weight decreased with 7%.

Trial Design

2 Treatment Groups

Ertugliflozin Treatment Arm
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

52 Total Participants · 2 Treatment Groups

Primary Treatment: Ertugliflozin 5 mg · Has Placebo Group · Phase 4

Ertugliflozin Treatment Arm
Drug
Experimental Group · 1 Intervention: Ertugliflozin 5 mg · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral tablet · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ertugliflozin
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

University Hospitals Cleveland Medical CenterLead Sponsor
300 Previous Clinical Trials
337,608 Total Patients Enrolled
Trevor L Jenkins, MDPrincipal InvestigatorUniversity Hospitals Cleveland Medical Center

Eligibility Criteria

Age 18 - 75 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top